Walkthrough of how recent trials and emerging LDL-lowering therapies are reshaping cholesterol management and prevention strategies.
Key Takeaways
- Evolocumab reduced cardiac events in patients without prior myocardial infarction or stroke
- Very low LDL levels achieved superior outcomes for secondary prevention in Ez-PAVE
- Oral PCSK9 inhibitor enlicitide demonstrated efficacy and safety in familial hypercholesterolemia patients